Sound Pharmaceuticals, the Seattle-based developer of treatments for hearing loss, said today it has received a $2.1 million contract from the Office of Naval Research, through its Science and Technology Division. The award will be used to expand ongoing development of the company’s lead drug, SPI-1005, for new types of hearing loss, and it will allow the company to identify new protein targets that could help expand its pipeline, said CEO Jonathan Kil. This is the third grant the company has received from the Naval research office since 2005.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
